Early outcomes associated with use of the Zenith TX2 Dissection Endovascular Graft for the treatment of Stanford type B aortic dissection.

Abstract Objective To evaluate short term outcomes related to the use of the Zenith TX2 Dissection Endovascular Graft (ZDEG) and the Zenith Dissection Bare stent (ZDES) for the treatment of Stanford type B aortic dissections. Design Retrospective multicentre case cohort study Methods Data was collated from 10 European institutions for patients with both complicated and uncomplicated type B aortic dissection treated with ZDEG and ZDES between 2011 and 2018. The primary endpoint was mortality at 30 and 90 days. Secondary endpoints included complications related to TEVAR, such as, type Ia endoleak, stroke, paraparesis/paraplegia and retrograde type A dissection. Statistical analysis was carried out using t-test, or one-way ANOVA and Chi-squared or Fisher’s Extact. Results 120 patients (87 male, age 62.7±12.2years), were treated either in the acute 76 (63.3%), subacute 16 (13.3%) or chronic 28 (23.3%) phase. Seven (5.8%) patients died within 30 days after the index procedure and 2 (1.7%) between 30 and 90 days. There was one instance of postoperative retrograde type A dissection in a patient treated for rupture. Stroke and paraplegia occurred in 3 (2.5%) and 5 (4.2%), patients, respectively. Eight (6.7%) patients had a type Ia endoleak in the perioperative period. There were no instances of paraplegia, no permanent dialysis and no requirement for adjunctive superior mesenteric or celiac artery stenting in the 33 (27.5%) patients who were treated by concurrent placement of ZDES distal to the ZDEG. The length and distal oversizing of ZDEG components used was less in this group. Conclusion The present series demonstrates a low (